This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human CG alpha / CGA Protein, His Tag
catalog :
CGA-H52H2
quantity :
100 ug, 1 mg
price :
350 USD, 1980 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
CGA-H52H2
product name :
Human CG alpha / CGA Protein, His Tag
quantity :
100 ug, 1 mg
price :
350 USD, 1980 USD
quantity & price :
$350/100ug,$1980/1mg (500ug × 2)
target :
CG alpha
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human CG alpha, His Tag (CGA-H52H2) is expressed from human 293 cells (HEK293). It contains AA Ala 25 - Ser 116 (Accession # AAH20782).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human CG alpha, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Chorionic gonadotrophin subunit alpha (CGA),a member of the glycoprotein hormones subunit alpha family, is also known as glycoprotein hormones alpha chain, choriogonadotropin alpha chain, follicle-stimulating hormone alpha chain (FSH-alpha), luteinizing hormone alpha chain (LSH-alpha) and thyroid-stimulating hormone alpha chain (TSH-alpha). The hormones human chorionic gonadotropin (hCG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and thyroid-stimulating hormone (TSH) are dimers consisting of alpha and beta subunits that are associated noncovalently. The alpha subunits (CGA) of these four human glycoprotein hormones are nearly identical, however, their beta chains are unique and confer biological specificity.
References :
(1) Sairam M.R., et al., 1977, Can. J. Biochem. 55:755-760.
(2) Rathnam P., et al., 1975, J. Biol. Chem. 250:6735-6746.
(3) Fan Q.R., et al., 2005, Nature 433:269-277.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments